Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting <em>SIRT1</em> in esophageal cancer Retraction in /10.3892/etm.2023.12288

Liu,Tao; Liang,Xiangsen; Sun,Yu; Yang,Shengzhuang

doi:10.3892/etm.2021.10624

Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting <em>SIRT1</em> in esophageal cancer

Retraction in: /10.3892/etm.2023.12288

Authors:
- Tao Liu
- Xiangsen Liang
- Yu Sun
- Shengzhuang Yang
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Guangxi International Zhuang Medical Hospital, Nanning, Guangxi 530201, P.R. China, Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530007, P.R. China
Published online on: August 17, 2021 https://doi.org/10.3892/etm.2021.10624
Article Number: 1190
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rapamycin, a secondary metabolite produced by Streptomyces hygroscopicus, is known for its pharmacological effects, especially antitumor and immunosuppressive activities. However, the antitumoral effects of rapamycin in human esophageal cancer (EC) are still poorly understood. To investigate the potential of rapamycin in EC treatment, sirtuin 1 (SIRT1) mRNA expression was quantified in the tissue of patients with EC or in EC cell lines using reverse transcription‑quantitative PCR. The protein levels of SIRT1 and PI3K/AKT/mTOR were measured via western blotting. Furthermore, cell viability, migration and invasion were investigated by Cell Counting Kit‑8, wound healing and Transwell assays, respectively. The present results suggested that SIRT1 expression was upregulated in EC. In vitro, the inhibitory effect of rapamycin on cell viability in EC was strengthened or weakened after small interfering (si)‑SIRT1 or pcDNA3.1/SIRT1 transfection. Furthermore, SIRT1 rescued the inhibitory effect of rapamycin on the migration and invasion of EC cells. In vivo, si‑SIRT1 or SIRT1 overexpression in mice could enhance or rescue the inhibitory effects of rapamycin on tumor growth. In addition, SIRT1 transfection rescued the decreased level of phosphorylated (p)‑PI3K, p‑AKT and p‑mTOR induced by rapamycin treatment. Taken together, the present results suggested that rapamycin suppressed the cell viability, migration, invasion and PI3K/AKT/mTOR signaling pathway in EC by negatively regulating SIRT1.

View Figures

View References

1	Short MW, Burgers K and Fry V: Esophageal cancer. Am Fam Physician. 95:22–28. 2017.PubMed/NCBI
2	North BJ and Verdin E: Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 5(224)2004.PubMed/NCBI View Article : Google Scholar
3	Zhang Y: Epidemiology of esophageal cancer. World J Gastroenterol. 19(5598)2013.PubMed/NCBI View Article : Google Scholar
4	Grabowska W, Sikora E and Bielak-Zmijewska A: Sirtuins, a promising target in slowing down the ageing process. Biogerontology. 18:447–476. 2017.PubMed/NCBI View Article : Google Scholar
5	Huang FL and Yu SJ: Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 41:210–215. 2018.PubMed/NCBI View Article : Google Scholar
6	Lu Z, Peng K, Wang N, Liu HM and Hou G: Downregulation of p70S6K enhances cell sensitivity to rapamycin in esophageal squamous cell carcinoma. J Immunol Res. 2016(7828916)2016.PubMed/NCBI View Article : Google Scholar
7	Du Z, Wang G, Cao Y, Hu CM, Yang K, Liu YZ, Zhang CZ, Zhang WH, Zhu ZT, Sun HZ, et al: Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs). Xenobiotica. 48:452–458. 2018.PubMed/NCBI View Article : Google Scholar
8	Liu C, Ma T, Jiang T, Jia G, Yang C, Peng Y, Qian Y, Wang R and Wang S: Abnormal increase of miR-4262 promotes cell proliferation and migration by targeting large tumor suppressor 1 in gliomas. Pathol Res Pract. 216(152778)2020.PubMed/NCBI View Article : Google Scholar
9	Boland PM and Burtness B: Esophageal carcinoma: Are modern targeted therapies shaking the rock? Curr Opin Oncol. 25:417–424. 2013.PubMed/NCBI View Article : Google Scholar
10	Pópulo H, Lopes J and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918. 2012.PubMed/NCBI View Article : Google Scholar
11	Guo W, Qian L, Zhang J, Zhang W, Morrison A, Hayes P, Wilson S, Chen T and Zhao J: Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling. J Neurosci Res. 89:1723–1736. 2011.PubMed/NCBI View Article : Google Scholar
12	Chueh S and Kahan B: Clinical application of sirolimus in renal transplantation: An update. Transpl Int. 18:261–277. 2005.PubMed/NCBI View Article : Google Scholar
13	Hirashima K, Baba Y, Watanabe M, Karashima RI, Sato N, Imamura Y, Nagai Y, Hayashi N, Iyama KI and Baba H: Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. Br J Cancer. 106:876–882. 2012.PubMed/NCBI View Article : Google Scholar
14	Zhang J, Peng J, Kong D, Wang X, Wang Z, Liu J, Yu W, Wu H, Long Z, Zhang W, et al: Silent information regulator 1 suppresses epithelial-to-mesenchymal transition in lung cancer cells via its regulation of mitochondria status. Life Sci. 280(119716)2021.PubMed/NCBI View Article : Google Scholar
15	Yang H, Bi Y, Xue L, Wang J, Lu Y, Zhang Z, Chen X, Chu Y, Yang R, Wang R and Liu G: Multifaceted modulation of SIRT1 in cancer and inflammation. Crit Rev Oncog. 20:49–64. 2015.PubMed/NCBI View Article : Google Scholar
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
17	Milovic V, Teller I, Murphy G, Caspary W and Stein J: Deoxycholic acid stimulates migration in colon cancer cells. Eur J Gastroenterol Hepatol. 13:945–949. 2001.PubMed/NCBI View Article : Google Scholar
18	Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. Publication. 327:963–965. 1996.
19	Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A and Oddo S: Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. Aging Cell. 11:326–335. 2012.PubMed/NCBI View Article : Google Scholar
20	Lv L, Shen Z, Zhang J, Zhang H, Dong J, Yan Y, Liu F, Jiang K, Ye Y and Wang S: Clinicopathological significance of SIRT1 expression in colorectal adenocarcinoma. Med Oncol. 31(965)2014.PubMed/NCBI View Article : Google Scholar
21	He Z, Yi J, Jin L, Pan B, Chen L and Song H: Overexpression of Sirtuin-1 is associated with poor clinical outcome in esophageal squamous cell carcinoma. Tumor Biol. 37:7139–7148. 2016.PubMed/NCBI View Article : Google Scholar
22	Guertin DA and Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med. 11:353–361. 2005.PubMed/NCBI View Article : Google Scholar
23	Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007.PubMed/NCBI View Article : Google Scholar
24	Hou G, Zhang Q, Wang L, Liu M, Wang J and Xue L: mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Lett. 290:248–254. 2010.PubMed/NCBI View Article : Google Scholar
25	Shen Z, Xu L, Li J and Zhang N: Capilliposide C sensitizes esophageal squamous carcinoma cells to oxaliplatin by inducing apoptosis through the PI3K/Akt/mTOR pathway. Med Sci Monit. 23:2096–2103. 2017.PubMed/NCBI View Article : Google Scholar
26	Sohda M and Kuwano H: Current status and future prospects for esophageal cancer treatment. Ann Thorac Cardiovasc Surg. 23:1–11. 2017.PubMed/NCBI View Article : Google Scholar
27	Hanigan MH and Devarajan P: Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Ther. 1:47–61. 2003.PubMed/NCBI
28	Xu Y, Xie Z, Shi Y, Zhang M, Pan J, Li Y and Lu H: Gefitinib single drug in treatment of advanced esophageal cancer. J Cancer Res Ther. 12 (Suppl):C295–C297. 2016.PubMed/NCBI View Article : Google Scholar
29	Fire A, Xu S, Montgomery M, Kostas S, Driver S and Mello C: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811. 1998.PubMed/NCBI View Article : Google Scholar
30	Hwang B, Madabushi A, Jin J, Lin S and Lu A: Histone/protein deacetylase SIRT1 is an anticancer therapeutic target. Am J Cancer Res. 4:211–221. 2014.PubMed/NCBI
31	Qin T, Liu W, Huo J, Li L, Zhang X, Shi X, Zhou J and Wang C: SIRT1 expression regulates the transformation of resistant esophageal cancer cells via the epithelial-mesenchymal transition. Biomed Pharmacother. 103:308–316. 2018.PubMed/NCBI View Article : Google Scholar
32	Sarbassov D, Ali S, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 22:159–168. 2006.PubMed/NCBI View Article : Google Scholar
33	Chan T, Rittenhouse S and Tsichlis P: AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. Ann Rev Biochem. 68:965–1014. 1999.PubMed/NCBI View Article : Google Scholar